Nurix Therapeutics
NRIX
22.73
+0.13
+0.58%
Nurix Therapeutics
US · NRIX
#2679 by market cap
Listed 2020
22.73
+0.13
+0.58%
Live - 5344 symbols - heartbeat 70s ago
· 2026-10-08 07:00
Pre-market
22.73
0.00%
After-hours
22.73
0.00%
- Market cap
- 2.36B
- P/E (TTM)i
- -6.57
- P/Bi
- 5.86
- EPSi
- -3.05
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on NRIX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- Total institutional ownership rose 0.3 percentage points.
Institutional ownership
- Held by institutions
- 114.25% +0.29pp
- Institutions
- 250
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund53.95%
Hedge Fund34.56%
VC/PE Fund16.50%
Public Company7.14%
Private Company1.16%
Individual/Insider0.93%
Insurance Company0.43%
Government Pension Fund0.22%
Sovereign Wealth Fund0.18%
Top holders as of 2026-06-30
BlackRock
8.45% · 8.77M sh
Vestal Point Capital, LP
7.76% · 8.05M sh
Deep Track Capital, LP
7.45% · 7.74M sh
Rubric Capital Management LP
6.96% · 7.23M sh
Perceptive Advisors LLC
5.33% · 5.54M sh
FMR
5.28% · 5.48M sh
T. Rowe Price Group, Inc.
5.24% · 5.44M sh
Vanguard Capital Management, LLC
4.99% · 5.18M sh
Morgan Stanley
4.53% · 4.70M sh
State Street Global Advisors
4.51% · 4.68M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 24 buys · 26 sells
| Name | Role | Stake |
|---|---|---|
| Arthur Sands | Chief Executive Officer | 0.73% |
| Gwenn Hansen | Chief Scientific Officer | 0.11% |
| Johannes Van Houte | Chief Financial Officer | 0.04% |
| David Lacey | Independent Chairperson | 0.03% |
| Julia Gregory | Independent Director | 0.01% |
| Christine Ring | General Counsel | 0.01% |
| Judith Reinsdorf | Independent Director | -- |
| Roy Baynes | Member of Medical Advisory Board | -- |
| Lori Kunkel | Independent Director | -- |
| Paul Silva | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Christine Ring | General Counsel | Derivative Exercise and Sale | -5,786 | $8.72–23.19 |
| 2026-09-01 | Christine Ring | General Counsel | Derivative Exercise and Sale | -5,787 | $8.72–26.64 |
| 2026-08-31 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Sale | -1,452 | $1.86–25.47 |
| 2026-08-04 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Sale | -4,356 | $1.86–25.00 |
| 2026-08-03 | Johannes Van Houte | Chief Financial Officer | Automatic Disposition | -4,761 | $23.89–24.65 |
| 2026-08-03 | Gwenn Hansen | Chief Scientific Officer | Automatic Disposition | -4,111 | $23.87–24.64 |
| 2026-08-02 | Christine Ring | General Counsel | Automatic Disposition | -10,802 | $23.05 |
| 2026-08-02 | Christine Ring | General Counsel | Derivative Exercise and Sale | -5,787 | $8.72–23.05 |
| 2026-07-29 | Johannes Van Houte | Chief Financial Officer | Derivative Exercise and Sale | -2,845 | $23.38 |
| 2026-07-29 | Johannes Van Houte | Chief Financial Officer | Derivative Exercise and Retained | +7,335 | -- |
| 2026-07-29 | Christine Ring | General Counsel | Derivative Exercise and Sale | -3,847 | $23.38 |
| 2026-07-29 | Christine Ring | General Counsel | Derivative Exercise and Retained | +6,333 | -- |
| 2026-07-29 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Sale | -3,847 | $23.38 |
| 2026-07-29 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Retained | +6,333 | -- |
| 2026-07-01 | Christine Ring | General Counsel | Derivative Exercise and Sale | -11,008 | $1.86–23.56 |
| 2026-06-24 | Christine Ring | General Counsel | Derivative Exercise and Sale | -28,935 | $7.26–20.06 |
| 2026-06-24 | Gwenn Hansen | Chief Scientific Officer | Automatic Disposition | -5,394 | $20.00 |
| 2026-06-01 | Christine Ring | General Counsel | Automatic Disposition | -4,726 | $16.60 |
| 2026-06-01 | Christine Ring | General Counsel | Derivative Exercise and Sale | -3,422 | $1.86–16.60 |
| 2026-05-14 | Julia Gregory | Independent Director | Other Derivative Acquisition | +31,250 | $15.86 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:00:07 · For reference only, not investment advice and not tailored to your situation.